Hope for a Cure Against HIV
Tucker, GA, May 28, 2011 -- Alain Lafeuillade (France) and Mario Stevenson (USA) co-authored a paper on HIV reservoirs that claims these reservoirs are the main hurdle to achieving HIV eradication. While antiretroviral therapy treatments have been successful in lengthening the life expectancy for HIV-infected individuals, a cure for HIV has not been found. The cure is not within reach primarily because of HIV reservoirs. While effective, antiretroviral therapy (ART) doesn't completely wipe out the HIV infection. Persistent infection is the result of small pools of virulent material known as HIV reservoirs, and these reservoirs are preventing the progress toward an HIV cure.
HIV persistence remains, even with antiretroviral (ART) treatment. Two critical questions arise when it comes to reservoirs. The first question is figuring out how to determine the nature of non-lymphocytic HIV reservoirs; the second question is finding a possible "threshold" where the HIV reservoir is kept low enough for the body to effectively control it. However, encouraging results were made in 2010 when the first person to ever be cured of HIV infection via a stem cell transplant. While this is apparently an isolated incident, it does show that HIV is curable. This development brought widespread optimism in the scientific community.
Therefore, the goal is to improve ART treatments to deal with latent HIV reservoirs, "purging" them in a way. Research indicates that a cocktail of drugs are needed to deal with compartment of the reservoir, sterilizing the virus and making it unable to replicate. These are the usual approaches to dealing with HIV-neutralizing the virus by taking away its ability to copy itself. Gene therapy combined with stem cell research into zinc finger nucleases designed to disrupt CCR5 expression have also been useful research topics. In fact, the stem cells implanted in the HIV-cured patient came from an individual with a rare CCR5 mutation.
HIV persistence via reservoirs is a top priority for researchers and health professionals throughout the globe. This paper provides information on the mechanisms of HIV persistence and a discussion on the critical questions facing researchers in the field. It also briefly discusses the need for better ART treatments and ends with a paragraph talking about the development of a task force dedicated to dealing with this subject. While the improvements in technology and medicine have made things better for HIV patients and improved the quality of their lives, HIV persistence via reservoirs has prevented an outright cure from being developed. The hope, as stated by the paper, is to turn the isolated HIV cure incident into a regular occurrence.
About the publication: The Search for a Cure for Persistent HIV Reservoirs. AIDS Rev. 2011; 13: 63-6
Informed Horizons, LLC
1860 Montreal Road
Tucker, GA USA
+1 770 573 3020
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hope for a Cure Against HIV here
News-ID: 177080 • Views: 2049
More Releases from Informed Horizons, LLC
Scientists Move Towards A HIV Cure
Dr. Alain Lafeuillade and Dr. Mario Stevenson, are pleased to announce the 5th International Workshop on HIV Persistence During Therapy, to be held December 6-9, 2011 in St Maarten, West Indies. The Workshop will be of invaluable importance for scientists working towards a HIV cure. Toulon, France, May 29, 2011 -- Dr. Alain Lafeuillade, Toulon, France and Dr. Mario Stevenson, University of Miami, USA are pleased to announce the 5th International
New Discoveries Expected at the Scientific Workshop on HIV Reservoirs
Tucker, GA - April 21, 2011 -- Controlling HIV replication without the need of life-long antiretroviral therapy (ART) is the next frontier scientists are addressing. Researchers involved in the fields of HIV reservoirs and eradication have just released the preliminary program of a workshop they will organize later this year, where scientific breakthroughs are expected. Fifteen years ago, when ART was discovered, a renewed optimism for a cure gained several scientists
Researchers United to Find a HIV cure
HIV persistence is an area of importance to many scientists working on a possible cure for HIV, and every two years a reference workshop is held to bring the world's top scientists together for a meeting of the minds. Researchers from several different fields will therefore attend its next edition, December 6-9, 2011. The preliminary program of this workshop has just been released, and the four-day seminar is packed with
More Releases for HIV
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: firstname.lastname@example.org or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral